Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00094081 · ClinicalTrials.gov registry record · Phase 3

Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer

A Phase 3 study, sponsored by Sanofi.

Completed
Registry status
Phase 3
Development phase
861
Enrollment target

NCT00094081: Completed Phase 3 study, sponsored by Sanofi.

NCT00094081 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 861 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00094081, a Phase 3 study, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 3
Development phase
861 participants
Enrollment target

Study Summary

The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.

Interventions

  • DRUG cisplatin
  • PROCEDURE Radiation Therapy
  • DRUG tirapazamine (SR259075)

Trial Details

FieldValue
Enrollment Target 861 participants
Start Date 2002-10
Est. Completion 2006-09
Phase Phase 3
Sanofi

713 total trials

What the finished NCT00094081 record still lists

NCT00094081 is an interventional study that assigns participants to a tested intervention. The registered 861 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher).

The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.

NCT00094081 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00094081 about?

NCT00094081 is a clinical study titled "Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer". The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.

What is the current status of trial NCT00094081?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 861 participants. The study started on 2002-10. Estimated completion is 2006-09.

What interventions are being tested in trial NCT00094081?

The interventions under investigation include: cisplatin (DRUG), Radiation Therapy (PROCEDURE), tirapazamine (SR259075) (DRUG).

Who is sponsoring clinical trial NCT00094081?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00094081's enrollment target sits among peer trials

861 380th of 2000 higher than 1,621 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05914116 · 862 participants · Phase 1

    A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • NCT04541381 · 860 participants · NA

    The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

  • NCT05211895 · 860 participants · Phase 3

    A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

  • NCT06161025 · 860 participants · Phase 2

    A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00094081, the US trial registry maintained by the National Library of Medicine. NCT00094081 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.